Niagen Bioscience price target raised to $16 from $13 at Canaccord

Canaccord raised the firm’s price target on Niagen Bioscience (NAGE) to $16 from $13 and keeps a Buy rating on the shares. Niagen Bioscience announced positive clinical study results that were recently published in the peer-reviewed journal Aging Cell, with the study centered around the safety of NAD+ supplementation on those with Werner syndrome, with secondary endpoints focused on NAD+ levels in patients with WS and other impacts on patients, including liver, kidney, and arterial health, the analyst tells investors in a research note. The published double-blind and placebo-controlled study highlighted the safety of NAD+ supplementation on patients with WS and also helped significantly increase NAD+ levels in blood by ~140%, along with improving various clinical markers for those with WS, the firm says, adding that this is a “positive first step.”